Amedeo Smart

Free Medical Literature Service


 

Amedeo

Autoimmune Disorders

  Free Subscription

Articles published in
Mult Scler
    October 2022
  1. PAUWELS A, Van Schependom J, Devolder L, Van Remoortel A, et al
    Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Mult Scler. 2022;28:1685-1696.
    >> Share

  2. FORD CC, Cohen JA, Goodman AD, Lindsey JW, et al
    Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
    Mult Scler. 2022;28:1729-1743.
    >> Share

  3. HARDY TA, Guo Y, Flanagan EP, Lucchinetti CF, et al
    The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions.
    Mult Scler. 2022;28:1710-1718.
    >> Share

  4. CAPANNA M, Signori A, Sormani MP
    Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.
    Mult Scler. 2022;28:1744-1751.
    >> Share

  5. ZARGHAMI A, van der Mei I, Hussain MA, Claflin SB, et al
    Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination.
    Mult Scler. 2022;28:1793-1807.
    >> Share

  6. GRAF J, Ng HS, Zhu F, Zhao Y, et al
    Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.
    Mult Scler. 2022;28:1825-1828.
    >> Share

  7. SALAMA S, Levy M
    Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder.
    Mult Scler. 2022;28:1663-1666.
    >> Share

  8. GAETANI L, Schoonheim MM
    Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
    Mult Scler. 2022;28:1831-1833.
    >> Share

  9. KOUBIYR I, Broeders TA, Deloire M, Brochet B, et al
    Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome.
    Mult Scler. 2022;28:1973-1982.
    >> Share

  10. ARNOLD DL, Sprenger T, Bar-Or A, Wolinsky JS, et al
    Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Mult Scler. 2022;28:1927-1936.
    >> Share

  11. BESSING B, Claflin SB, Taylor BV, Blizzard L, et al
    Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss.
    Mult Scler. 2022;28:1983-1996.
    >> Share

    September 2022
  12. BUHLER A, Wolbers M, Model F, Wang Q, et al
    Recurrent disability progression endpoints in multiple sclerosis clinical trials.
    Mult Scler. 2022 Sep 30:13524585221125382. doi: 10.1177/13524585221125382.
    >> Share

  13. ALEXANDER S, Braisher M, Tur C, Chataway J, et al
    The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis.
    Mult Scler. 2022 Sep 30:13524585221124043. doi: 10.1177/13524585221124043.
    >> Share

  14. STRIK M, Eijlers AJ, Dekker I, Broeders TA, et al
    Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis.
    Mult Scler. 2022 Sep 30:13524585221125372. doi: 10.1177/13524585221125372.
    >> Share

  15. SARACENO L, Pirro F, Stigliano R, Agostoni EC, et al
    Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders.
    Mult Scler. 2022 Sep 28:13524585221125360. doi: 10.1177/13524585221125360.
    >> Share

  16. BRUIJSTENS AL, Stingl C, Guzel C, Stoop MP, et al
    Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood.
    Mult Scler. 2022 Sep 24:13524585221125369. doi: 10.1177/13524585221125369.
    >> Share

  17. POL-PATIL J, Glanz B, Safar L, Misasi E, et al
    MeTooMS: Sexual, physical, and emotional abuse experience among women with multiple sclerosis.
    Mult Scler. 2022 Sep 24:13524585221122169. doi: 10.1177/13524585221122169.
    >> Share

  18. CHANG I, Kappos L, Giovannoni G, Calabresi PA, et al
    Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
    Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997.
    >> Share

  19. COHEN JA, Lublin FD, Lock C, Pelletier D, et al
    Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
    Mult Scler. 2022 Sep 14:13524585221122156. doi: 10.1177/13524585221122156.
    >> Share

  20. VAN LIEROP ZY, Noteboom S, Steenwijk MD, van Dam M, et al
    Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
    Mult Scler. 2022 Sep 3:13524585221118676. doi: 10.1177/13524585221118676.
    >> Share

  21. MCGINLEY MP, Lapin B
    The value of patient-reported outcome measures for multiple sclerosis.
    Mult Scler. 2022;28:1489-1490.
    >> Share

  22. MARIGNIER R
    It is imperative to reconsider the concept of seronegative NMOSD.
    Mult Scler. 2022;28:1654-1655.
    >> Share

  23. ROGAWSKI DS, Nirschl JJ, McDonald J, Nie E, et al
    A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma.
    Mult Scler. 2022;28:1651-1654.
    >> Share

  24. STRIJBIS EM, Repovic P, Mostert J, Bowen JD, et al
    The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
    Mult Scler. 2022;28:1606-1619.
    >> Share

  25. KLISTORNER S, Barnett MH, Graham SL, Wang C, et al
    The expansion and severity of chronic MS lesions follows a periventricular gradient.
    Mult Scler. 2022;28:1504-1514.
    >> Share

  26. XIANG B, Brier MR, Kanthamneni M, Wen J, et al
    Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Mult Scler. 2022;28:1515-1525.
    >> Share

  27. THEBAULT S, Bose G, Booth R, Freedman MS, et al
    Serum neurofilament light in MS: The first true blood-based biomarker?
    Mult Scler. 2022;28:1491-1497.
    >> Share

  28. PORTACCIO E, Amato MP
    Reliable change indices for cognitive assessment of patients with multiple sclerosis.
    Mult Scler. 2022 Sep 1:13524585221116273. doi: 10.1177/13524585221116273.
    >> Share

    August 2022
  29. MEATON I, Altokhis A, Allen CM, Clarke MA, et al
    Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
    Mult Scler. 2022 Aug 26:13524585221118677. doi: 10.1177/13524585221118677.
    >> Share

  30. BROWNLEE WJ, Wolf C, Hartung HP, Dingermann T, et al
    Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
    Mult Scler. 2022 Aug 24:13524585221116269. doi: 10.1177/13524585221116269.
    >> Share

  31. ALTOKHIS AI, Hibbert AM, Allen CM, Mougin O, et al
    Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis.
    Mult Scler. 2022 Aug 24:13524585221114750. doi: 10.1177/13524585221114750.
    >> Share

  32. YOUNG CA, Mills RJ, Langdon D, Rog DJ, et al
    Measuring coping in multiple sclerosis: The Coping Index-MS.
    Mult Scler. 2022 Aug 24:13524585221114004. doi: 10.1177/13524585221114004.
    >> Share

  33. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
    Mult Scler. 2022 Aug 15:13524585221114007. doi: 10.1177/13524585221114007.
    >> Share

  34. BLYAU S, Koubiyr I, Saranathan M, Coupe P, et al
    Differential vulnerability of thalamic nuclei in multiple sclerosis.
    Mult Scler. 2022 Aug 12:13524585221114247. doi: 10.1177/13524585221114247.
    >> Share

  35. CONWAY SE, Pua DKA, Holroyd KB, Galetta K, et al
    Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.
    Mult Scler. 2022 Aug 11:13524585221117949. doi: 10.1177/13524585221117949.
    >> Share

  36. WILLIAMS T, Tur C, Eshaghi A, Doshi A, et al
    Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial.
    Mult Scler. 2022 Aug 9:13524585221114441. doi: 10.1177/13524585221114441.
    >> Share

  37. CIFTCI KAVAKLIOGLU B, Erdman L, Goldenberg A, Kavaklioglu C, et al
    Machine learning classification of multiple sclerosis in children using optical coherence tomography.
    Mult Scler. 2022 Aug 9:13524585221112605. doi: 10.1177/13524585221112605.
    >> Share

  38. UCCELLI A, Freedman MS
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No.
    Mult Scler. 2022;28:1326-1328.
    >> Share

  39. PERUZZOTTI-JAMETTI L, Pluchino S
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary.
    Mult Scler. 2022;28:1328-1329.
    >> Share

  40. KARUSSIS D, Kassis I, Petrou P
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES.
    Mult Scler. 2022;28:1324-1326.
    >> Share

  41. GIBBONS E, Whittam D, Elhadd K, Bhojak M, et al
    Progressive myelin oligodendrocyte glycoprotein-associated demyelination mimicking leukodystrophy.
    Mult Scler. 2022;28:1481-1484.
    >> Share

  42. ROSTASY K
    A rare but distinct and unique phenotype of MOGAD.
    Mult Scler. 2022;28:1485.
    >> Share

  43. SESEL AL, Sharpe L, Beadnall HN, Barnett MH, et al
    A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression.
    Mult Scler. 2022;28:1392-1401.
    >> Share

    July 2022
  44. TAGGE IJ, Leppert IR, Fetco D, Campbell JS, et al
    Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
    Mult Scler. 2022 Jul 28:13524585221110585. doi: 10.1177/13524585221110585.
    >> Share

  45. ZHONG M, van der Walt A, Monif M, Hodgkinson S, et al
    Prediction of relapse activity when switching to cladribine for multiple sclerosis.
    Mult Scler. 2022 Jul 27:13524585221111677. doi: 10.1177/13524585221111677.
    >> Share

  46. KLISTORNER S, Barnett MH, Klistorner A
    Mechanisms of central brain atrophy in multiple sclerosis.
    Mult Scler. 2022 Jul 21:13524585221111684. doi: 10.1177/13524585221111684.
    >> Share

  47. JOHNSSON M, Farman HH, Blennow K, Zetterberg H, et al
    No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Mult Scler. 2022 Jul 20:13524585221108080. doi: 10.1177/13524585221108080.
    >> Share

  48. MAGYARI M, Joensen H, Kopp TI, Pontieri L, et al
    Changes in prognosis of the Danish multiple sclerosis population over time.
    Mult Scler. 2022 Jul 13:13524585221110582. doi: 10.1177/13524585221110582.
    >> Share

  49. KRIEGER SC, Antoine A, Sumowski JF
    EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold.
    Mult Scler. 2022 Jul 13:13524585221108297. doi: 10.1177/13524585221108297.
    >> Share

  50. ANNA KARIN H, Erik S, Tim S, Lars F, et al
    The impact of bariatric surgery on disease activity and progression of multiple sclerosis: A nationwide matched cohort study.
    Mult Scler. 2022 Jul 7:13524585221107095. doi: 10.1177/13524585221107095.
    >> Share

  51. LADAKIS DC, Yao PJ, Vreones M, Blommer J, et al
    Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis.
    Mult Scler. 2022 Jul 5:13524585221106290. doi: 10.1177/13524585221106290.
    >> Share

  52. MANUEL ESCOBAR J, Cortese M, Edan G, Freedman MS, et al
    Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
    Mult Scler. 2022;28:1277-1285.
    >> Share

  53. W KOCH M, Mostert J, Repovic P, Bowen JD, et al
    Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
    Mult Scler. 2022;28:1286-1298.
    >> Share

  54. ANDERSEN JB, Wandall-Holm MF, Andersen PK, Sellebjerg F, et al
    Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort.
    Mult Scler. 2022;28:1239-1247.
    >> Share

  55. GIOVANNONI G, Singer BA, Issard D, Jack D, et al
    Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
    Mult Scler. 2022;28:1219-1228.
    >> Share

  56. EISELE P, Wittayer M, Weber CE, Platten M, et al
    Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
    Mult Scler. 2022 Jul 1:13524585221106338. doi: 10.1177/13524585221106338.
    >> Share

    June 2022
  57. PROUSKAS SE, Schoonheim MM, Huiskamp M, Steenwijk MD, et al
    A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
    Mult Scler. 2022 Jun 28:13524585221103134. doi: 10.1177/13524585221103134.
    >> Share

  58. CREE BA, Selmaj KW, Steinman L, Comi G, et al
    Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
    >> Share

  59. MARASTONI D, Crescenzo F, Pisani AI, Zuco C, et al
    Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Mult Scler. 2022 Jun 28:13524585221104014. doi: 10.1177/13524585221104014.
    >> Share

  60. MAGNE F, Cellerino M, Balletto E, Aluan K, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.
    >> Share

  61. HEMOND CC, Baek J, Ionete C, Reich DS, et al
    Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study.
    Mult Scler. 2022 Jun 24:13524585221102921. doi: 10.1177/13524585221102921.
    >> Share

  62. SCHIAVETTI I, Cordioli C, Stromillo ML, Teresa Ferro M, et al
    Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
    Mult Scler. 2022 Jun 23:13524585221102918. doi: 10.1177/13524585221102918.
    >> Share

  63. GARJANI A, Liu BJ, Allen CM, Gunzler DD, et al
    Decentralised clinical trials in multiple sclerosis research.
    Mult Scler. 2022 Jun 23:13524585221100401. doi: 10.1177/13524585221100401.
    >> Share

  64. MAAROUF A, Audoin B, Gherib S, El Mendili MM, et al
    Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.
    Mult Scler. 2022 Jun 20:13524585221102587. doi: 10.1177/13524585221102587.
    >> Share

  65. GUERRERA G, Mandelli A, Finardi A, Orrico M, et al
    Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
    Mult Scler. 2022 Jun 20:13524585221102158. doi: 10.1177/13524585221102158.
    >> Share

  66. LAZZAROTTO A, Tonietto M, Poirion E, Battaglini M, et al
    Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartment imaging study.
    Mult Scler. 2022 Jun 16:13524585221096975. doi: 10.1177/13524585221096975.
    >> Share

  67. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
    Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
    Mult Scler. 2022 Jun 13:13524585221096964. doi: 10.1177/13524585221096964.
    >> Share

  68. AL-LOUZI O, Manukyan S, Donadieu M, Absinta M, et al
    Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study.
    Mult Scler. 2022 Jun 8:13524585221097560. doi: 10.1177/13524585221097560.
    >> Share

  69. SCHMIERER K, Wiendl H, Oreja-Guevara C, Centonze D, et al
    Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
    Mult Scler. 2022 Jun 7:13524585221099413. doi: 10.1177/13524585221099413.
    >> Share

  70. BRUNE S, Hogestol EA, de Rodez Benavent SA, Berg-Hansen P, et al
    Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221097296. doi: 10.1177/13524585221097296.
    >> Share

  71. LEAVITT VM, Dworkin JD, Buyukturkoglu K, Riley CS, et al
    Summary metrics of memory subnetwork functional connectivity alterations in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221099169. doi: 10.1177/13524585221099169.
    >> Share

  72. BEREK K, Hegen H, Hocher J, Auer M, et al
    Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
    Mult Scler. 2022 Jun 2:13524585221097566. doi: 10.1177/13524585221097566.
    >> Share

  73. CARCAMO C, Ciampi E
    Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
    Mult Scler. 2022;28:1032-1033.
    >> Share

  74. PIEHL F, Mathew T
    Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.
    Mult Scler. 2022;28:1028-1029.
    >> Share

  75. MATEEN FJ
    Low-dose rituximab should be used for treating MS in resource-limited settings: No.
    Mult Scler. 2022;28:1030-1032.
    >> Share

  76. WRIGHT S
    MOG antibody-associated longitudinal extensive myelitis after Oxford-Astra Zeneca's COVID-19 vaccination.
    Mult Scler. 2022;28:1163.
    >> Share

  77. DAMS L, Kraemer M, Becker J
    MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination.
    Mult Scler. 2022;28:1159-1162.
    >> Share

  78. RINALDI V, Bellucci G, Romano A, Bozzao A, et al
    ADEM after ChAdOx1 nCoV-19 vaccine: A case report.
    Mult Scler. 2022;28:1151-1154.
    >> Share

  79. PODDA J, Tacchino A, Pedulla L, Monti Bragadin M, et al
    Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.
    Mult Scler. 2022;28:1009-1019.
    >> Share

    May 2022
  80. COFRE LIZAMA LE, Strik M, Van der Walt A, Kilpatrick TJ, et al
    Gait stability reflects motor tracts damage at early stages of multiple sclerosis.
    Mult Scler. 2022 May 21:13524585221094464. doi: 10.1177/13524585221094464.
    >> Share

  81. FADDA G, Waters P, Woodhall M, Brown RA, et al
    Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.
    Mult Scler. 2022 May 17:13524585221093789. doi: 10.1177/13524585221093789.
    >> Share

  82. GONZALEZ-MARTINEZ A, Bose G, Chitnis T
    Anti-CGRP therapies for migraine in multiple sclerosis patients.
    Mult Scler. 2022 May 14:13524585221096353. doi: 10.1177/13524585221096353.
    >> Share

  83. SCHWARZ T, Otto C, Jones TC, Pache F, et al
    Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
    Mult Scler. 2022 May 14:13524585221094478. doi: 10.1177/13524585221094478.
    >> Share

  84. LEUNG MW, Bazelier MT, Souverein PC, Uitdehaag BM, et al
    Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
    Mult Scler. 2022 May 14:13524585221094218. doi: 10.1177/13524585221094218.
    >> Share

  85. ALMRAMHI MM, Storm CS, Kia DA, Coneys R, et al
    The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study.
    Mult Scler. 2022 May 14:13524585221092644. doi: 10.1177/13524585221092644.
    >> Share

  86. CHIARAVALLOTI ND, DeLuca J, Salter A, Amato MP, et al
    The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
    Mult Scler. 2022 May 9:13524585221088190. doi: 10.1177/13524585221088190.
    >> Share

  87. MANGLANI HR, Fisher ME, Duraney EJ, Nicholas JA, et al
    A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures.
    Mult Scler. 2022 May 9:13524585221088731. doi: 10.1177/13524585221088731.
    >> Share

  88. HYUN JW, Lee HL, Park J, Kim J, et al
    Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
    Mult Scler. 2022;28:989-992.
    >> Share

  89. VALSASINA P, Gobbi C, Zecca C, Rovira A, et al
    Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis.
    Mult Scler. 2022;28:885-899.
    >> Share

  90. RENSEL M, Zabeti A, Mealy MA, Cimbora D, et al
    Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for 4 years in the N-MOmentum trial.
    Mult Scler. 2022;28:925-932.
    >> Share

  91. ROSENSTEIN I, Axelsson M, Novakova L, Blennow K, et al
    Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
    Mult Scler. 2022;28:872-884.
    >> Share


  92. ACTRIMS Forum 2022.
    Mult Scler. 2022;28.
    >> Share

    April 2022
  93. SPRENGER T, Kappos L, Sormani MP, Miller AE, et al
    Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Mult Scler. 2022 Apr 29:13524585221089534. doi: 10.1177/13524585221089534.
    >> Share

  94. DEGRAEVE B, Sequeira H, Mecheri H, Lenne B, et al
    Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?
    Mult Scler. 2022 Apr 27:13524585221091067. doi: 10.1177/13524585221091067.
    >> Share

  95. MANZANO GS, Rice DR, Klawiter EC, Matiello M, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Apr 27:13524585221092309. doi: 10.1177/13524585221092309.
    >> Share

  96. ZABALZA A, Arrambide G, Otero-Romero S, Pappolla A, et al
    Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
    Mult Scler. 2022 Apr 27:13524585221089540. doi: 10.1177/13524585221089540.
    >> Share

  97. SIMONEAU G, Pellegrini F, Debray TP, Rouette J, et al
    Recommendations for the use of propensity score methods in multiple sclerosis research.
    Mult Scler. 2022 Apr 6:13524585221085733. doi: 10.1177/13524585221085733.
    >> Share

  98. CREE BA, Arnold DL, Fox RJ, Gold R, et al
    Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Mult Scler. 2022 Apr 5:13524585221083194. doi: 10.1177/13524585221083194.
    >> Share

  99. KALINCIK T, Kister I, Bacon TE, Malpas CB, et al
    Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
    Mult Scler. 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577.
    >> Share

  100. MOCCIA M, Affinito G, Ronga B, Giordana R, et al
    Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).
    Mult Scler. 2022;28:597-607.
    >> Share

  101. GRATCH D, Zhovtis Ryerson L
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.
    Mult Scler. 2022;28:695-696.
    >> Share

  102. INES CIPLEA A, Kurzeja A, Thiel S, Haben S, et al
    Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
    Mult Scler. 2022 Apr 1:13524585221083982. doi: 10.1177/13524585221083982.
    >> Share

  103. TZANETAKOS D, Tzartos JS, Vakrakou AG, Breza M, et al
    Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study.
    Mult Scler. 2022;28:718-729.
    >> Share

  104. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter.
    Mult Scler. 2022;28:697-706.
    >> Share

  105. ALY L, Strauss EM, Feucht N, Weiss I, et al
    Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders.
    Mult Scler. 2022;28:522-531.
    >> Share

  106. ABDEL-MANNAN O, Klein A, Bachar Zipori A, Ben-Sira L, et al
    Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.
    Mult Scler. 2022;28:676-679.
    >> Share

  107. ROTSTEIN DL
    Radiologically isolated syndrome and the possibility of preclinical disease activity in aquaporin-4 antibody NMOSD.
    Mult Scler. 2022;28:679-680.
    >> Share

  108. KIM KH, Kim SH, Park NY, Hyun JW, et al
    Reappraisal of CSF-specific oligoclonal bands in Asia.
    Mult Scler. 2022;28:665-668.
    >> Share

  109. KUHLE J, Daizadeh N, Benkert P, Maceski A, et al
    Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
    Mult Scler. 2022;28:573-582.
    >> Share

  110. BAJRAMI A, Magliozzi R, Pisani AI, Pizzini FB, et al
    Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS.
    Mult Scler. 2022;28:550-560.
    >> Share

  111. KIM H, Lee EJ, Kim S, Choi LK, et al
    Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder.
    Mult Scler. 2022;28:512-521.
    >> Share

  112. VALENTINE TR, Alschuler KN, Ehde DM, Kratz AL, et al
    Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis.
    Mult Scler. 2022;28:620-631.
    >> Share

    March 2022
  113. GASPERI C, Hapfelmeier A, Schneider A, Kuhn KA, et al
    Association of pregnancies with risk of multiple sclerosis.
    Mult Scler. 2022 Mar 18:13524585221080542. doi: 10.1177/13524585221080542.
    >> Share

  114. PORTACCIO E, Pasto L, Razzolini L, Moiola L, et al
    Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
    Mult Scler. 2022 Mar 16:13524585221079598. doi: 10.1177/13524585221079598.
    >> Share

  115. RIEMENSCHNEIDER M, Hvid LG, Ringgaard S, Nygaard MKE, et al
    Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
    Mult Scler. 2022 Mar 16:13524585221079200. doi: 10.1177/13524585221079200.
    >> Share

  116. CARLSON A, McGinley MP
    Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.
    Mult Scler. 2022 Mar 16:13524585221081985. doi: 10.1177/13524585221081985.
    >> Share

  117. LIANG G, Zhu F, Mirza AI, Bar-Or A, et al
    Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases.
    Mult Scler. 2022 Mar 16:13524585221079533. doi: 10.1177/13524585221079533.
    >> Share

  118. JACOBS BM, Watson C, Marshall C, Noyce A, et al
    No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 16:13524585221075744. doi: 10.1177/13524585221075744.
    >> Share

  119. DALGAS U, Stenager E, Hvid LG
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: Commentary.
    Mult Scler. 2022 Mar 16:13524585211072702. doi: 10.1177/13524585211072702.
    >> Share

  120. MOTL RW, Sandroff BM
    Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect-Yes.
    Mult Scler. 2022 Mar 16:13524585211061651. doi: 10.1177/13524585211061651.
    >> Share

  121. HEESEN C, Rosenkranz SC
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No.
    Mult Scler. 2022 Mar 16:13524585211064968. doi: 10.1177/13524585211064968.
    >> Share

  122. WENDEL EM, Bertolini A, Kousoulos L, Rauchenzauner M, et al
    Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
    Mult Scler. 2022 Mar 14:13524585221081090. doi: 10.1177/13524585221081090.
    >> Share

  123. BSTEH G, Hegen H, Berek K, Altmann P, et al
    Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
    Mult Scler. 2022 Mar 12:13524585221079744. doi: 10.1177/13524585221079744.
    >> Share

  124. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 12:13524585221079044. doi: 10.1177/13524585221079044.
    >> Share

  125. GARTNER J, Hauser SL, Bar-Or A, Montalban X, et al
    Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
    Mult Scler. 2022 Mar 10:13524585221078825. doi: 10.1177/13524585221078825.
    >> Share

  126. ARNOLD DL, Piani-Meier D, Bar-Or A, Benedict RH, et al
    Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Mult Scler. 2022 Mar 9:13524585221076717. doi: 10.1177/13524585221076717.
    >> Share

  127. BEBO BF JR, Allegretta M, Landsman D, Zackowski KM, et al
    Pathways to cures for multiple sclerosis: A research roadmap.
    Mult Scler. 2022;28:331-345.
    >> Share

  128. HAUSER SL, Cross AH, Winthrop K, Wiendl H, et al
    Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Mult Scler. 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731.
    >> Share

  129. PITTOCK SJ, Fujihara K, Palace J, Berthele A, et al
    Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
    Mult Scler. 2022;28:480-486.
    >> Share

  130. PORTACCIO E, Tudisco L, Pasto L, Razzolini L, et al
    Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
    Mult Scler. 2022;28:472-479.
    >> Share

  131. VAVASOUR IM, Sun P, Graf C, Yik JT, et al
    Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.
    Mult Scler. 2022;28:418-428.
    >> Share

    February 2022
  132. TUR C, Dubessy AL, Otero-Romero S, Amato MP, et al
    The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
    Mult Scler. 2022 Feb 23:13524585211069068. doi: 10.1177/13524585211069068.
    >> Share

  133. SHAFIN N, Ismail CAN, Mustafa MZ, Ghani N, et al
    Thematic analysis of multiple sclerosis research by enhanced strategic diagram.
    Mult Scler. 2022 Feb 15:13524585221075542. doi: 10.1177/13524585221075542.
    >> Share


  134. Erratum to "Assessing diagnosis disclosure and concealment in multiple sclerosis: building a framework for moving forward".
    Mult Scler. 2022 Feb 11:13524585221079450. doi: 10.1177/13524585221079450.
    >> Share

  135. BECK ES, Maranzano J, Luciano NJ, Parvathaneni P, et al
    Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.
    Mult Scler. 2022 Feb 10:13524585211069167. doi: 10.1177/13524585211069167.
    >> Share

  136. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Patten S, et al
    Productivity loss among people with early multiple sclerosis: A Canadian study.
    Mult Scler. 2022 Feb 9:13524585211069070. doi: 10.1177/13524585211069070.
    >> Share

  137. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
    The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents.
    Mult Scler. 2022 Feb 7:13524585211061521. doi: 10.1177/13524585211061521.
    >> Share

  138. HOLM HANSEN R, Hojsgaard Chow H, Talbot J, Buhelt S, et al
    Peripheral helper T cells in the pathogenesis of multiple sclerosis.
    Mult Scler. 2022 Feb 3:13524585211067696. doi: 10.1177/13524585211067696.
    >> Share

  139. DOBSON R, Chung K
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.
    Mult Scler. 2022;28:326-327.
    >> Share

  140. COYLE PK, Syritsyna O
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
    Mult Scler. 2022;28:183-185.
    >> Share

  141. BERMEL RA
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - No.
    Mult Scler. 2022;28:185-187.
    >> Share

  142. FOX RJ, Tintore M
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary.
    Mult Scler. 2022;28:187-188.
    >> Share

  143. HILLERT J, Tsai JA, Nouhi M, Glaser A, et al
    A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Mult Scler. 2022;28:237-246.
    >> Share

  144. ZHENG Y, Dudman J, Chen JT, Mahajan KR, et al
    Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
    Mult Scler. 2022;28:198-205.
    >> Share

  145. PFEUFFER S, Rolfes L, Hackert J, Kleinschnitz K, et al
    Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
    Mult Scler. 2022;28:257-268.
    >> Share

    January 2022
  146. LIAO CM, Kuo WY, Kung PT, Chuan CH, et al
    Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan.
    Mult Scler. 2022 Jan 25:13524585211061341. doi: 10.1177/13524585211061341.
    >> Share

  147. NAKAMURA K, Zheng Y, Ontaneda D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yes.
    Mult Scler. 2022 Jan 22:13524585211066313. doi: 10.1177/13524585211066313.
    >> Share

  148. MUHLAU M
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No.
    Mult Scler. 2022 Jan 22:13524585211063622. doi: 10.1177/13524585211063622.
    >> Share

  149. ROVIRA A, Pareto D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis - Commentary.
    Mult Scler. 2022 Jan 22:13524585211069363. doi: 10.1177/13524585211069363.
    >> Share

  150. KEVER A, Riley CS, Leavitt VM
    Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis.
    Mult Scler. 2022 Jan 16:13524585211070496. doi: 10.1177/13524585211070496.
    >> Share

  151. P MOSS B, Miller DM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward.
    Mult Scler. 2022 Jan 11:13524585211069668. doi: 10.1177/13524585211069668.
    >> Share

  152. BELVISI D, Canevelli M, Marfia GA, Ferraro E, et al
    Response to "Frailty in multiple sclerosis: A closer look at the deficit accumulation framework".
    Mult Scler. 2022 Jan 8:13524585211068150. doi: 10.1177/13524585211068150.
    >> Share

  153. ZIAEI A, Lavery AM, Shao XM, Adams C, et al
    Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.
    Mult Scler. 2022 Jan 8:13524585211069926. doi: 10.1177/13524585211069926.
    >> Share

  154. VAN KEMPEN ZL, Hogenboom L, Killestein J
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
    Mult Scler. 2022 Jan 7:13524585211064441. doi: 10.1177/13524585211064441.
    >> Share

  155. COHEN JA, Bermel RA, Grossman CI, Hersh CM, et al
    Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
    Mult Scler. 2022 Jan 7:13524585211061343. doi: 10.1177/13524585211061343.
    >> Share

  156. THOMPSON AJ, Carroll W, Ciccarelli O, Comi G, et al
    Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
    Mult Scler. 2022;28:16-28.
    >> Share

  157. TARDO L, Wang C, Rajaram V, Greenberg BM, et al
    Pediatric paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian teratoma.
    Mult Scler. 2022;28:160-163.
    >> Share

  158. ABDEL-MANNAN O, Hacohen Y
    Aquaporin-4 antibody neuromyelitis optica spectrum disorder: A paraneoplastic disease?
    Mult Scler. 2022;28:163-164.
    >> Share

  159. TAJFIROUZ D, Padungkiatsagul T, Beres S, Moss HE, et al
    Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder.
    Mult Scler. 2022;28:149-153.
    >> Share

  160. COMABELLA M, Clarke MA, Schaedelin S, Tintore M, et al
    CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
    Mult Scler. 2022;28:71-81.
    >> Share

  161. SIGNORIELLO E, Lus G, Bonavita S, Lanzillo R, et al
    Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
    Mult Scler. 2022;28:93-101.
    >> Share

    December 2021
  162. GAITAN MI, Sanchez M, Farez MF, Fiol MP, et al
    The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina.
    Mult Scler. 2021 Dec 31:13524585211067521. doi: 10.1177/13524585211067521.
    >> Share

  163. BERNARDI G, Biagioli T, Malpassi P, De Michele T, et al
    The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study.
    Mult Scler. 2021 Dec 30:13524585211064121. doi: 10.1177/13524585211064121.
    >> Share

  164. CAVACO S, Ferreira I, Moreira I, Santos E, et al
    Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review.
    Mult Scler. 2021 Dec 30:13524585211066598. doi: 10.1177/13524585211066598.
    >> Share

  165. VAN KEMPEN ZL, Toorop AA, Sellebjerg F, Giovannoni G, et al
    Extended dosing of monoclonal antibodies in multiple sclerosis.
    Mult Scler. 2021 Dec 24:13524585211065711. doi: 10.1177/13524585211065711.
    >> Share

  166. NG HS, Zhu F, Kingwell E, Zhao Y, et al
    Disease-modifying drugs for multiple sclerosis and subsequent health service use.
    Mult Scler. 2021 Dec 24:13524585211063403. doi: 10.1177/13524585211063403.
    >> Share

  167. FERNANDEZ RS, Crivelli L, Pedreira ME, Allegri RF, et al
    Computational basis of decision-making impairment in multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211059308. doi: 10.1177/13524585211059308.
    >> Share

  168. ZANOTTO T, Lynch SG, Hausdorff JM, Sosnoff JJ, et al
    Frailty in multiple sclerosis: A closer look at the deficit accumulation framework.
    Mult Scler. 2021 Dec 21:13524585211061332. doi: 10.1177/13524585211061332.
    >> Share

  169. ROLFES L, Meuth SG
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
    Mult Scler. 2021 Dec 21:13524585211055593. doi: 10.1177/13524585211055593.
    >> Share

  170. TOOROP AA, Rispens T, Strijbis EM, van Oosten BW, et al
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211052168. doi: 10.1177/13524585211052168.
    >> Share

  171. JANUEL E, De Seze J, Vermersch P, Maillart E, et al
    Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
    Mult Scler. 2021 Dec 21:13524585211049737. doi: 10.1177/13524585211049737.
    >> Share

  172. COLES AJ, Jones JL, Vermersch P, Traboulsee A, et al
    Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
    Mult Scler. 2021 Dec 9:13524585211061335. doi: 10.1177/13524585211061335.
    >> Share

  173. ROVIRA A, Corral JF, Auger C, Valverde S, et al
    Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients.
    Mult Scler. 2021 Dec 3:13524585211061339. doi: 10.1177/13524585211061339.
    >> Share

  174. LEEKOFF M, Culpepper W, Jin S, Lee-Wilk T, et al
    Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
    Mult Scler. 2021 Dec 2:13524585211058361. doi: 10.1177/13524585211058361.
    >> Share

  175. VAN KEMPEN ZL, Killestein J, Hartung HP
    Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients.
    Mult Scler. 2021;27:2123-2125.
    >> Share

  176. NOURBAKHSH B
    Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
    Mult Scler. 2021;27:2290.
    >> Share

  177. LEHMANN H, Zveik O, Levin N, Brill L, et al
    Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses.
    Mult Scler. 2021;27:2232-2239.
    >> Share

  178. OH J, Suthiphosuwan S, Sati P, Absinta M, et al
    Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS.
    Mult Scler. 2021;27:2199-2208.
    >> Share

    November 2021
  179. SARKAR P, Redondo J, Hares K, Bailey S, et al
    Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
    Mult Scler. 2021 Nov 29:13524585211060686. doi: 10.1177/13524585211060686.
    >> Share

  180. OTERO-ROMERO S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, et al
    Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.
    Mult Scler. 2021 Nov 29:13524585211053001. doi: 10.1177/13524585211053001.
    >> Share

  181. KIRA JI, Nakahara J, Sazonov DV, Kurosawa T, et al
    Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Mult Scler. 2021 Nov 17:13524585211055934. doi: 10.1177/13524585211055934.
    >> Share

  182. SCHORR EM, Kurz D, Rossi KC, Zhang M, et al
    Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
    Mult Scler. 2021 Nov 17:13524585211051316. doi: 10.1177/13524585211051316.
    >> Share

  183. MARRIE RA, McKay K
    Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
    Mult Scler. 2021 Nov 17:13524585211055787. doi: 10.1177/13524585211055787.
    >> Share

  184. MAUBEUGE N, Deloire MS, Brochet B, Charre-Morin J, et al
    Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
    Mult Scler. 2021 Nov 12:13524585211054006. doi: 10.1177/13524585211054006.
    >> Share

  185. MOUMDJIAN L, Moens B, Van Wijmeersh B, Leman M, et al
    Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study.
    Mult Scler. 2021 Nov 2:13524585211054000. doi: 10.1177/13524585211054000.
    >> Share

  186. CREE BA, Bennett JL, Kim HJ, Weinshenker BG, et al
    Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
    Mult Scler. 2021;27:2052-2061.
    >> Share

  187. DAHLKE F, Arnold DL, Aarden P, Ganjgahi H, et al
    Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
    Mult Scler. 2021;27:2062-2076.
    >> Share

    October 2021
  188. MISICKA E, Davis MF, Kim W, Brugger SW, et al
    A higher burden of multiple sclerosis genetic risk confers an earlier onset.
    Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
    >> Share

  189. PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
    Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
    Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
    >> Share

  190. BERGAMASCHI R, Montomoli C
    Air pollution is a risk factor for multiple sclerosis - Yes.
    Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.
    >> Share

  191. DELGADO-GARCIA G, Corona T
    Air pollution is a risk factor for multiple sclerosis - No.
    Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.
    >> Share

  192. SAHRAIAN MA
    Air pollution is a risk factor for multiple sclerosis - Commentary.
    Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.
    >> Share

  193. ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
    Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
    >> Share

  194. UHER T, Havrdova EK, Benkert P, Bergsland N, et al
    Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
    Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
    >> Share

  195. VILLOSLADA P
    Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
    Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.
    >> Share

  196. WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
    Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
    Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
    >> Share

  197. SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
    Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
    Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
    >> Share

  198. BOSMA AR, Murley C, Aspling J, Hillert J, et al
    Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
    Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
    >> Share

  199. BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
    Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
    >> Share

  200. GROTHE M, Ellenberger D, von Podewils F, Stahmann A, et al
    Epilepsy as a predictor of disease progression in multiple sclerosis.
    Mult Scler. 2021 Oct 1:13524585211046739. doi: 10.1177/13524585211046739.
    >> Share

  201. SANDROFF BM, Motl RW, Amato MP, Brichetto G, et al
    Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
    Mult Scler. 2021 Oct 1:13524585211048397. doi: 10.1177/13524585211048397.
    >> Share

  202. BSTEH G, Durauer S, Assar H, Hegen H, et al
    Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
    Mult Scler. 2021 Oct 1:13524585211049391. doi: 10.1177/13524585211049391.
    >> Share

  203. GEORGIEVA ZG, Dffinger R, Kumararatne D, Coles AJ, et al
    Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2021 Oct 1:13524585211046786. doi: 10.1177/13524585211046786.
    >> Share

  204. CAMERON MH, Hildebrand A, Hugos CL, Judd GI, et al
    Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2021 Oct 1:13524585211046898. doi: 10.1177/13524585211046898.
    >> Share

  205. ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
    Hypertension and hypertension severity in Hispanics/Latinx with MS.
    Mult Scler. 2021;27:1894-1901.
    >> Share

  206. ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
    Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
    Mult Scler. 2021;27:1829-1837.
    >> Share

  207. KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
    A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
    Mult Scler. 2021;27:1864-1874.
    >> Share

  208. KOCH MW, Metz L, Cutter G
    An enrichment strategy for clinical trials in SPMS.
    Mult Scler. 2021;27:1884-1893.
    >> Share

    September 2021
  209. BUSSAS M, Grahl S, Pongratz V, Berthele A, et al
    Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
    Mult Scler. 2021 Sep 30:13524585211044957. doi: 10.1177/13524585211044957.
    >> Share

  210. KEVER A, Leavitt VM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey.
    Mult Scler. 2021 Sep 9:13524585211037581. doi: 10.1177/13524585211037581.
    >> Share

  211. KRYSKO KM, Anderson A, Singh J, McPolin K, et al
    Risk factors for peripartum depression in women with multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211041108. doi: 10.1177/13524585211041108.
    >> Share

  212. WOJCIK C, Jaworski M 3rd, Dwyer MG, Youngs M, et al
    Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211044672. doi: 10.1177/13524585211044672.
    >> Share

  213. TREMLETT H, Okuda DT, Lebrun-Frenay C
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
    Mult Scler. 2021 Sep 8:13524585211035951. doi: 10.1177/13524585211035951.
    >> Share

  214. GNANAPAVAN S
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Yes.
    Mult Scler. 2021 Sep 8:13524585211040223. doi: 10.1177/13524585211040223.
    >> Share

  215. MAKHANI N
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.
    Mult Scler. 2021 Sep 8:13524585211044951. doi: 10.1177/13524585211044951.
    >> Share

  216. BRADLEY L
    Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
    Mult Scler. 2021 Sep 5:13524585211035737. doi: 10.1177/13524585211035737.
    >> Share

  217. ENZINGER C
    Slowly expanding lesions are a marker of progressive multiple sclerosis - Commentary.
    Mult Scler. 2021 Sep 3:13524585211040225. doi: 10.1177/13524585211040225.
    >> Share

  218. HARTUNG HP, Meuth SG, Thompson AJ
    Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
    Mult Scler. 2021;27:1473-1476.
    >> Share

  219. GOLD R, Arnold DL, Bar-Or A, Fox RJ, et al
    Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Mult Scler. 2021 Sep 1:13524585211037909. doi: 10.1177/13524585211037909.
    >> Share

    August 2021
  220. CONWAY DS, Marck CH
    Comorbidities require special attention in minorities with multiple sclerosis.
    Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.
    >> Share

  221. BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
    Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
    Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
    >> Share

  222. COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
    A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
    >> Share

  223. GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
    Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
    >> Share

  224. ALONSO R, Galleguillos L
    Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
    Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.
    >> Share

  225. ABBADESSA G, Lavorgna L, Treaba CA, Bonavita S, et al
    Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039111. doi: 10.1177/13524585211039111.
    >> Share

  226. BUTLER PAGNOTTI R, Hua LH, Miller JB
    Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039112. doi: 10.1177/13524585211039112.
    >> Share

  227. TILLAUT H, Degremont A, Kerbrat S, Roux J, et al
    Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
    Mult Scler. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.
    >> Share

  228. ROMMER PS, Bsteh G, Berger T, Zettl UK, et al
    SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
    Mult Scler. 2021 Aug 13:13524585211039128. doi: 10.1177/13524585211039128.
    >> Share

  229. MARCHESI O, Bonacchi R, Valsasina P, Preziosa P, et al
    Functional and structural MRI correlates of executive functions in multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211033184. doi: 10.1177/13524585211033184.
    >> Share

  230. CLAFLIN SB, Campbell JA, Mason DF, Kalincik T, et al
    The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211035948. doi: 10.1177/13524585211035948.
    >> Share

  231. WEINSTOCK-GUTTMAN B, Bermel R, Cutter G, Freedman MS, et al
    Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
    Mult Scler. 2021 Aug 12:13524585211035740. doi: 10.1177/13524585211035740.
    >> Share

  232. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study.
    Mult Scler. 2021 Aug 11:13524585211034826. doi: 10.1177/13524585211034826.
    >> Share

  233. AYADI N, Oertel FC, Asseyer S, Rust R, et al
    Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2021 Aug 11:13524585211032801. doi: 10.1177/13524585211032801.
    >> Share

  234. ZHENG F, Li Y, Zhuo Z, Duan Y, et al
    Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800.
    >> Share

  235. COMI G, Dadon Y, Sasson N, Steinerman JR, et al
    CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Aug 11:13524585211032803. doi: 10.1177/13524585211032803.
    >> Share

  236. PANDIT L
    Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines.
    Mult Scler. 2021;27:1320-1322.
    >> Share

  237. KANINIA S, Grammatikos A, Urankar K, Renowden SA, et al
    CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.
    Mult Scler. 2021;27:1464-1467.
    >> Share

    July 2021
  238. SORMANI MP, Schiavetti I, Landi D, Carmisciano L, et al
    SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
    Mult Scler. 2021 Jul 30:13524585211035318. doi: 10.1177/13524585211035318.
    >> Share

  239. ROTSTEIN D, Maxwell C, Tu K, Gatley J, et al
    High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis.
    Mult Scler. 2021 Jul 30:13524585211031791. doi: 10.1177/13524585211031791.
    >> Share

  240. PITTERI M, Magliozzi R, Nicholas R, Ziccardi S, et al
    Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.
    Mult Scler. 2021 Jul 30:13524585211032510. doi: 10.1177/13524585211032510.
    >> Share

  241. UHR L, Mateen FJ
    COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.
    Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647.
    >> Share

  242. LAURSON-DOUBE J, Rijke N, Helme A, Baneke P, et al
    Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211030207. doi: 10.1177/13524585211030207.
    >> Share

  243. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801.
    >> Share

  244. LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
    Risk of depression in multiple sclerosis across disease-modifying therapies.
    Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
    >> Share

  245. BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
    Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
    >> Share

  246. MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
    A smartphone sensor-based digital outcome assessment of multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
    >> Share

  247. HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
    Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
    Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
    >> Share

  248. WIJERATNE T, Carroll W
    World Brain Day 2021: Global campaign to stop multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
    >> Share

  249. HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
    Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
    Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
    >> Share

  250. VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
    Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
    Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
    >> Share

  251. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    >> Share

  252. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    >> Share

  253. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    >> Share

  254. ESHAGHI A
    Towards an objective classification of multiple sclerosis.
    Mult Scler. 2021;27:1151-1152.
    >> Share

  255. CALDITO NG, O'Leary S, Stuve O
    Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Mult Scler. 2021;27:1306-1308.
    >> Share

  256. MARRIE RA, Patel R, Bernstein CN, Bolton JM, et al
    Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.
    Mult Scler. 2021;27:1284-1292.
    >> Share

  257. CENCIONI MT, Ali R, Nicholas R, Muraro PA, et al
    Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS.
    Mult Scler. 2021;27:1187-1197.
    >> Share

  258. OTALLAH S
    Acute disseminated encephalomyelitis in children and adults: A focused review emphasizing new developments.
    Mult Scler. 2021;27:1153-1160.
    >> Share

    June 2021
  259. SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
    Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
    >> Share

  260. MIZELL R, Chen H, Lambe J, Saidha S, et al
    Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
    Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
    >> Share

  261. BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
    Altered anterior default mode network dynamics in progressive multiple sclerosis.
    Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
    >> Share

  262. HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
    Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
    Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
    >> Share

  263. WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
    High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
    Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
    >> Share

  264. VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
    Acute and chronic synaptic pathology in multiple sclerosis gray matter.
    Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
    >> Share

  265. CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
    Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
    Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
    >> Share

  266. SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
    Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
    Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
    >> Share

  267. KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
    The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
    >> Share

  268. GARJANI A, Hunter R, Law GR, Middleton RM, et al
    Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
    Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
    >> Share

  269. SCHMIERER K, Giovannoni G
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary.
    Mult Scler. 2021;27:1006-1007.
    >> Share

  270. SCALFARI A
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
    Mult Scler. 2021;27:1002-1004.
    >> Share

  271. CROSS AH, Naismith RT
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
    Mult Scler. 2021;27:1004-1005.
    >> Share

  272. ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
    Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
    Mult Scler. 2021;27:989-1001.
    >> Share

  273. MORROW SA, Conway D, Fuchs T, Wojcik C, et al
    Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
    Mult Scler. 2021;27:1077-1087.
    >> Share

  274. NAYAK S, Sechi E, Flanagan EP, Messina S, et al
    Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
    Mult Scler. 2021;27:1037-1045.
    >> Share

  275. REDER AT
    Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
    Mult Scler. 2021;27:1008-1013.
    >> Share

    May 2021
  276. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    >> Share

  277. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    >> Share

  278. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    >> Share

  279. MCMURRAN CE
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
    >> Share

  280. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
    >> Share

  281. HOHLFELD R
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
    >> Share

  282. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    >> Share

  283. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    >> Share

  284. DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
    Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
    >> Share

  285. WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
    Staging and stratifying cognitive dysfunction in multiple sclerosis.
    Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
    >> Share

  286. BROWNLEE WJ, Solomon AJ
    Misdiagnosis of multiple sclerosis: Time for action.
    Mult Scler. 2021;27:805-806.
    >> Share

  287. CORREA DG, de Souza Lima FC, da Cruz Bezerra D, Coutinho AC Junior, et al
    COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence?
    Mult Scler. 2021;27:973-976.
    >> Share

  288. VALENCIA-SANCHEZ C, Flanagan EP
    COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? - Commentary.
    Mult Scler. 2021;27:976-977.
    >> Share

  289. LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
    Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
    Mult Scler. 2021;27:883-894.
    >> Share

  290. CAI MT, Zheng Y, Shen CH, Yang F, et al
    Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
    Mult Scler. 2021;27:871-882.
    >> Share

  291. CACCIAGUERRA L, Rocca MA, Storelli L, Radaelli M, et al
    Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach.
    Mult Scler. 2021;27:841-854.
    >> Share

  292. KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
    Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
    Mult Scler. 2021;27:895-902.
    >> Share

    April 2021
  293. HOLLEN C, Rice J, Park M, Yadav V, et al
    Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
    Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
    >> Share

  294. GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
    The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
    Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
    >> Share

  295. VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
    Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
    >> Share

  296. KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
    Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
    Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
    >> Share

  297. HARRISON AM, Safari R, Mercer T, Picariello F, et al
    Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
    Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
    >> Share

  298. ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
    Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
    Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
    >> Share

  299. ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
    Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
    Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
    >> Share

  300. PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
    Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
    Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
    >> Share

  301. CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
    Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
    >> Share

  302. CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
    Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
    >> Share

  303. FLEMING KM, Coote SB, Herring MP
    Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
    Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
    >> Share

  304. SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
    Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
    Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
    >> Share

  305. D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
    Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
    Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
    >> Share

  306. CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
    Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
    Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
    >> Share

  307. COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
    Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
    Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
    >> Share

  308. ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
    >> Share

  309. TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
    A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
    >> Share

  310. BESSING B, Honan CA, van der Mei I, Taylor BV, et al
    Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
    Mult Scler. 2021;27:767-777.
    >> Share

  311. VAN DAM M, Hulst HE, Schoonheim MM
    Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
    Mult Scler. 2021;27:491-493.
    >> Share

  312. MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
    Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mult Scler. 2021;27:790-794.
    >> Share

  313. BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
    Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
    Mult Scler. 2021;27:729-741.
    >> Share

  314. KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
    Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Mult Scler. 2021;27:695-705.
    >> Share

  315. SECHI E, Messina S, Keegan BM, Buciuc M, et al
    Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
    Mult Scler. 2021;27:667-673.
    >> Share

  316. DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
    Cladribine transfer into human milk: A case report.
    Mult Scler. 2021;27:799-801.
    >> Share

    March 2021
  317. HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
    Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
    Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
    >> Share

  318. THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
    Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
    Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
    >> Share

  319. CREE BA, Cohen JA, Reder AT, Tomic D, et al
    Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
    Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
    >> Share

  320. PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
    Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
    Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
    >> Share

  321. LEE LE, Vavasour IM, Dvorak A, Liu H, et al
    Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
    Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
    >> Share

  322. HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
    Childhood obesity and multiple sclerosis: A Mendelian randomization study.
    Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
    >> Share

  323. BRIGGS FB, Krill D, Hill E, Conway DS, et al
    Age of hypertension onset in multiple sclerosis patients.
    Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
    >> Share

  324. MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
    Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
    >> Share

  325. SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
    The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
    Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
    >> Share

  326. MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
    Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
    Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
    >> Share

  327. LORSCHEIDER J
    When does a heap become a heap?
    Mult Scler. 2021;27:329-330.
    >> Share

  328. BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
    Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
    Mult Scler. 2021;27:410-419.
    >> Share

  329. HYUN JW, Kwon YN, Lee HL, Jeong WK, et al
    Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease.
    Mult Scler. 2021;27:449-452.
    >> Share

    February 2021
  330. SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
    Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
    >> Share

  331. FOX RJ, Raska P, Barro C, Karafa M, et al
    Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
    >> Share

  332. MHANNA E, Nouchi A, Louapre C, De Paz R, et al
    Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
    Mult Scler. 2021 Feb 25:1352458521991433. doi: 10.1177/1352458521991433.
    >> Share

  333. COPETTI M, Liu D
    Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
    Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
    >> Share

  334. HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
    The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
    Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
    >> Share

  335. BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
    Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
    Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
    >> Share

  336. LEMA DOPICO A, Choi S, Hua J, Li X, et al
    Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
    Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
    >> Share

  337. HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
    Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
    >> Share

  338. BESSING B, Hussain MA, Claflin SB, Chen J, et al
    Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
    >> Share

  339. BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
    Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
    Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
    >> Share

  340. MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
    The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
    Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
    >> Share

  341. VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
    Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
    >> Share

  342. KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
    Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
    >> Share

  343. DAS J, Snowden JA, Burman J, Freedman MS, et al
    Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
    >> Share


  344. Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
    Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
    >> Share

  345. NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
    Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
    Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
    >> Share

  346. YEH EA
    Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
    Mult Scler. 2021;27:165-166.
    >> Share

  347. TANASESCU R, Gran B
    Uncovering the underhanded: B-cell depletion therapies and severe viral infections - Commentary on 'Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease'.
    Mult Scler. 2021;27:323-324.
    >> Share

  348. LUCIANI L, Ninove L, Zandotti C, Chalvignac V, et al
    Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease.
    Mult Scler. 2021;27:320-323.
    >> Share

  349. SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
    Data harmonization for collaborative research among MS registries: A case study in employment.
    Mult Scler. 2021;27:281-289.
    >> Share

  350. SECHI E, Krecke KN, Pittock SJ, Dubey D, et al
    Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.
    Mult Scler. 2021;27:303-308.
    >> Share

    January 2021
  351. MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
    A multiple sclerosis disease progression measure based on cumulative disability.
    Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
    >> Share

  352. JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
    Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
    Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
    >> Share

  353. BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
    An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
    Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
    >> Share

  354. ROOS I, Leray E, Frascoli F, Casey R, et al
    Determinants of therapeutic lag in multiple sclerosis.
    Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
    >> Share

  355. FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
    Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
    Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
    >> Share

  356. GONZALEZ-ESCAMILLA G, Groppa S
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
    Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
    >> Share

  357. SATI P, Reich DS
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
    Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
    >> Share

  358. LOUAPRE C, Beigneux Y
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
    Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
    >> Share

  359. ROLLOT F, Casey R, Leray E, Debouverie M, et al
    Cumulative effects of therapies on disability in relapsing multiple sclerosis.
    Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
    >> Share

  360. MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
    Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
    Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
    >> Share

  361. AMATO MP, Portaccio E, De Meo E
    Understanding the pathophysiology of cognitive changes in MS: A step forward.
    Mult Scler. 2021;27:4-5.
    >> Share

  362. BISTROM M, Hultdin J, Sundstrom P
    Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
    Mult Scler. 2021;27:161-162.
    >> Share

  363. AL-ARAJI S, Ciccarelli O
    A possible case of serum sickness after ocrelizumab infusion - Commentary.
    Mult Scler. 2021;27:158-159.
    >> Share

  364. CARNERO CONTENTTI E, Correale J
    Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - Yes.
    Mult Scler. 2021;27:13-15.
    >> Share

  365. JURYNCZYK M, Messina S, Palace J
    Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - No.
    Mult Scler. 2021;27:15-16.
    >> Share

  366. LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
    Elevated D-dimer as an immediate response to alemtuzumab treatment.
    Mult Scler. 2021;27:151-154.
    >> Share

  367. ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
    Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
    Mult Scler. 2021;27:39-51.
    >> Share

  368. GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
    Cerebellar volume loss in radiologically isolated syndrome.
    Mult Scler. 2021;27:130-133.
    >> Share

    December 2020
  369. NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
    Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
    Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
    >> Share

  370. GALLO A, Bisecco A
    Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
    Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
    >> Share

  371. LEAVITT VM, Kever A
    Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
    Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
    >> Share

  372. PLOUGHMAN M
    Psychological resilience explains functional variability across people with multiple sclerosis - No.
    Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
    >> Share

  373. COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
    Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
    Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
    >> Share

  374. HYLAND MH, Robb JF
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
    Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
    >> Share

  375. MOCCIA M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
    Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
    >> Share

  376. D'HAESELEER M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
    Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
    >> Share

  377. CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
    Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
    >> Share

  378. FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
    Serum ceramide levels are altered in multiple sclerosis.
    Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
    >> Share

  379. CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
    Depression in multiple sclerosis across the adult lifespan.
    Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
    >> Share

  380. TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
    Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
    Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
    >> Share

  381. NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
    Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
    Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
    >> Share

  382. JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
    Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
    >> Share

  383. BRIGGS F
    Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
    >> Share

  384. KOUBIYR I, Deloire M, Brochet B, Besson P, et al
    Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
    Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
    >> Share

  385. VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
    Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
    Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
    >> Share

  386. RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
    Accurate classification of secondary progression in multiple sclerosis using a decision tree.
    Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
    >> Share

  387. SHAH S
    Real-world evidence: One tweet at a time.
    Mult Scler. 2020;26:1965-1966.
    >> Share

  388. COETZEE T, Thompson AJ
    Atlas of MS 2020: Informing global policy change.
    Mult Scler. 2020;26:1807-1808.
    >> Share

  389. PILUTTI LA, Fakolade A
    Rehabilitation should be prescribed acutely in motor relapses - Commentary.
    Mult Scler. 2020;26:1825-1827.
    >> Share

  390. YONG KP, Kim HJ
    Smelling the danger.
    Mult Scler. 2020;26:1960-1961.
    >> Share

    November 2020
  391. STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
    Youth with multiple sclerosis have low levels of fitness.
    Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
    >> Share

  392. ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
    An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
    Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
    >> Share

  393. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
    >> Share

  394. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
    >> Share

  395. IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
    Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
    Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
    >> Share

  396. LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
    COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
    Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
    >> Share

  397. CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
    Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
    >> Share

  398. GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
    Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
    Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
    >> Share

  399. PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
    Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
    >> Share

  400. HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
    Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
    Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
    >> Share

  401. SACCO R, Braga A, Disanto G, Digesu GA, et al
    Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
    Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
    >> Share

  402. KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
    The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
    Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
    >> Share

  403. AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
    The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
    Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
    >> Share

  404. WALTON C, King R, Rechtman L, Kaye W, et al
    Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
    Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
    >> Share

  405. HEDSTROM AK, Olsson T, Alfredsson L
    Cotinine as a measure of smoking in observational studies of multiple sclerosis.
    Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
    >> Share

  406. LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
    Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
    Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
    >> Share

  407. BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
    Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
    Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
    >> Share

    October 2020
  408. LOZINSKI BM, Yong VW
    Exercise and the brain in multiple sclerosis.
    Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
    >> Share

  409. AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
    The emerging role of artificial intelligence in multiple sclerosis imaging.
    Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
    >> Share

  410. PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
    Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
    Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
    >> Share

  411. STRIK M, Chard DT, Dekker I, Meijer KA, et al
    Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
    Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
    >> Share

  412. KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
    Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
    Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
    >> Share

  413. TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
    Parietal dysfunctional connectivity in depression in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
    >> Share

  414. JAEGER S, Paul F, Finke C
    Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
    >> Share

  415. BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
    Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
    >> Share

  416. SIDORE C, Orru V, Cocco E, Steri M, et al
    PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity.
    Mult Scler. 2020 Oct 14:1352458520963937. doi: 10.1177/1352458520963937.
    >> Share

  417. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
    >> Share

  418. CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
    'Posture second' strategy predicts disability progression in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
    >> Share

  419. VEREB D, Toth E, Bozsik B, Kiraly A, et al
    Altered brain network function during attention-modulated visual processing in multiple sclerosis.
    Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
    >> Share

  420. LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
    Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
    Mult Scler. 2020;26:1476-1485.
    >> Share

  421. CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
    Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
    Mult Scler. 2020;26:1550-1559.
    >> Share

  422. HULST HE, Penner IK
    Cognition and its relation to brain health in patients with MS.
    Mult Scler. 2020;26:1611-1613.
    >> Share

  423. HOBART J, Giovannoni G
    Cognition and its relation to brain health in patients with MS: Response to letter.
    Mult Scler. 2020;26:1613-1614.
    >> Share

  424. AZEVEDO CJ, Zamvil SS
    New cases of vasculitis after alemtuzumab.
    Mult Scler. 2020;26:1606-1608.
    >> Share

    September 2020
  425. PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
    Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
    >> Share

  426. FERRE L, Mogavero A, Clarelli F, Moiola L, et al
    Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
    >> Share

  427. BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
    School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
    Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
    >> Share

  428. CALVI A, Haider L, Prados F, Tur C, et al
    In vivo imaging of chronic active lesions in multiple sclerosis.
    Mult Scler. 2020 Sep 23:1352458520958589. doi: 10.1177/1352458520958589.
    >> Share

  429. RIVA A, Barcella V, Benatti SV, Capobianco M, et al
    Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
    Mult Scler. 2020 Sep 17:1352458520952310. doi: 10.1177/1352458520952310.
    >> Share

  430. MOIOLA L, Barcella V, Benatti S, Capobianco M, et al
    The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.
    Mult Scler. 2020 Sep 17:1352458520952311. doi: 10.1177/1352458520952311.
    >> Share

  431. FEYS P, Swinnen E
    Powered exoskeletons for walking in multiple sclerosis.
    Mult Scler. 2020 Sep 15:1352458520958351. doi: 10.1177/1352458520958351.
    >> Share

  432. WEE SK, Ho CY, Tan SL, Ong CH, et al
    Enhancing quality of life in progressive multiple sclerosis with powered robotic exoskeleton.
    Mult Scler. 2020 Sep 15:1352458520943080. doi: 10.1177/1352458520943080.
    >> Share

  433. CORDANI C, Hidalgo de la Cruz M, Meani A, Valsasina P, et al
    MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes.
    Mult Scler. 2020 Sep 14:1352458520958356. doi: 10.1177/1352458520958356.
    >> Share

  434. ZHANG Y, Taylor BV, Simpson S Jr, Blizzard L, et al
    Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype.
    Mult Scler. 2020 Sep 14:1352458520958369. doi: 10.1177/1352458520958369.
    >> Share

  435. BRIGGS FB
    Nicotinic acetylcholine receptors alpha7 and alpha9 modifies tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Sep 14:1352458520958361. doi: 10.1177/1352458520958361.
    >> Share

  436. KUNCHOK A, Flanagan EP, Krecke KN, Chen JJ, et al
    MOG-IgG1 and co-existence of neuronal autoantibodies.
    Mult Scler. 2020 Sep 10:1352458520951046. doi: 10.1177/1352458520951046.
    >> Share

  437. MARTINO M, Magioncalda P, El Mendili MM, Droby A, et al
    Depression is associated with disconnection of neurotransmitter-related nuclei in multiple sclerosis.
    Mult Scler. 2020 Sep 10:1352458520948214. doi: 10.1177/1352458520948214.
    >> Share

  438. CHEN J, Taylor B, Blizzard L, Simpson-Yap S, et al
    Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis.
    Mult Scler. 2020 Sep 3:1352458520954167. doi: 10.1177/1352458520954167.
    >> Share

  439. YILMAZER C, Lamers I, Solaro C, Feys P, et al
    Clinical perspective on pain in multiple sclerosis.
    Mult Scler. 2020 Sep 3:1352458520952015. doi: 10.1177/1352458520952015.
    >> Share

  440. HAWTON A, Goodwin E, Boddy K, Freeman J, et al
    Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
    Mult Scler. 2020 Sep 3:1352458520954172. doi: 10.1177/1352458520954172.
    >> Share

  441. JOISTEN N, Proschinger S, Rademacher A, Schenk A, et al
    High-intensity interval training reduces neutrophil-to-lymphocyte ratio in persons with multiple sclerosis during inpatient rehabilitation.
    Mult Scler. 2020 Sep 3:1352458520951382. doi: 10.1177/1352458520951382.
    >> Share

  442. CICCARELLI O, Cohen JA, Thompson A
    Response of the multiple sclerosis community to COVID-19.
    Mult Scler. 2020;26:1134-1136.
    >> Share

  443. YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
    MS, pregnancy and COVID-19.
    Mult Scler. 2020;26:1137-1146.
    >> Share

  444. MECA-LALLANA V
    COVID-19 will change MS care forever - Yes.
    Mult Scler. 2020;26:1147-1148.
    >> Share

  445. PREZIOSA P, Rocca MA, Filippi M
    COVID-19 will change MS care forever - No.
    Mult Scler. 2020;26:1149-1151.
    >> Share

    August 2020
  446. MIDAGLIA L, Otero S, Baro F, Montalban X, et al
    Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy.
    Mult Scler. 2020 Aug 28:1352458520952022. doi: 10.1177/1352458520952022.
    >> Share

  447. DISANTO G, Ripellino P, Riccitelli GC, Sacco R, et al
    De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.
    Mult Scler. 2020 Aug 25:1352458520952036. doi: 10.1177/1352458520952036.
    >> Share

  448. BOFFA G, Sbragia E, Raiola AM, Varaldo R, et al
    Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases.
    Mult Scler. 2020 Aug 25:1352458520914818. doi: 10.1177/1352458520914818.
    >> Share

  449. SMITH AD, Prokopiusova T, Jones R, Burge T, et al
    Functional electrical stimulation for foot drop in people with multiple sclerosis: The relevance and importance of addressing quality of movement.
    Mult Scler. 2020 Aug 24:1352458520923958. doi: 10.1177/1352458520923958.
    >> Share

  450. SADIGH G, Lava N, Switchenko J, Duszak R Jr, et al
    Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence.
    Mult Scler. 2020 Aug 18:1352458520913977. doi: 10.1177/1352458520913977.
    >> Share

  451. JORDAN AL, Yang J, Fisher CJ, Racke MK, et al
    Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Mult Scler. 2020 Aug 18:1352458520949158. doi: 10.1177/1352458520949158.
    >> Share

  452. SEYMAN E, Jones A, Guenette M, Vosoughi R, et al
    Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.
    Mult Scler. 2020 Aug 11:1352458520948212. doi: 10.1177/1352458520948212.
    >> Share

  453. MOSS BP, Mahajan KR, Bermel RA, Hellisz K, et al
    Multiple sclerosis management during the COVID-19 pandemic.
    Mult Scler. 2020 Aug 10:1352458520948231. doi: 10.1177/1352458520948231.
    >> Share

  454. BROWNLEE WJ
    COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
    Mult Scler. 2020 Aug 7:1352458520948211. doi: 10.1177/1352458520948211.
    >> Share

  455. WURM H, Attfield K, Iversen AK, Gold R, et al
    Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
    Mult Scler. 2020 Aug 7:1352458520943791. doi: 10.1177/1352458520943791.
    >> Share

  456. DERSCH R, Wehrum T, Fahndrich S, Engelhardt M, et al
    COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
    Mult Scler. 2020 Aug 7:1352458520943783. doi: 10.1177/1352458520943783.
    >> Share

  457. JAWORSKI MG 3RD, Fuchs TA, Dwyer MG, Wojcik C, et al
    Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years.
    Mult Scler. 2020 Aug 6:1352458520946019. doi: 10.1177/1352458520946019.
    >> Share

  458. GERALDES R, Jurynczyk M, Dos Passos GR, Pichler A, et al
    The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease.
    Mult Scler. 2020 Aug 6:1352458520943777. doi: 10.1177/1352458520943777.
    >> Share

  459. GUISSET F, Lolli V, Bugli C, Perrotta G, et al
    The central vein sign in multiple sclerosis patients with vascular comorbidities.
    Mult Scler. 2020 Aug 4:1352458520943785. doi: 10.1177/1352458520943785.
    >> Share

  460. ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
    Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
    Mult Scler. 2020 Aug 4:1352458520946005. doi: 10.1177/1352458520946005.
    >> Share

  461. LIPP I, Foster C, Stickland R, Sgarlata E, et al
    Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: A behavioural and MRI study.
    Mult Scler. 2020 Aug 4:1352458520943788. doi: 10.1177/1352458520943788.
    >> Share

  462. ABBOUD H
    Iatrogenic demyelinating disorders: New insights, new culprits.
    Mult Scler. 2020;26:1129-1130.
    >> Share

    July 2020
  463. RINGH MV, Hagemann-Jensen M, Needhamsen M, Kullberg S, et al
    Methylome and transcriptome signature of bronchoalveolar cells from multiple sclerosis patients in relation to smoking.
    Mult Scler. 2020 Jul 30:1352458520943768. doi: 10.1177/1352458520943768.
    >> Share


  464. CORRIGENDUM to "Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder".
    Mult Scler. 2020 Jul 24:1352458520945512. doi: 10.1177/1352458520945512.
    >> Share

  465. SIMPSON-YAP S, Oddy WH, Taylor B, Lucas RM, et al
    High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis.
    Mult Scler. 2020 Jul 23:1352458520943087. doi: 10.1177/1352458520943087.
    >> Share

  466. INOJOSA H, Ziemssen T
    How to reduce the delay of diagnosing secondary progression in multiple sclerosis.
    Mult Scler. 2020 Jul 22:1352458520943799. doi: 10.1177/1352458520943799.
    >> Share

  467. CONWAY DS, Thompson NR, Meng X, Johnson K, et al
    Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
    Mult Scler. 2020 Jul 16:1352458520936214. doi: 10.1177/1352458520936214.
    >> Share

  468. HUBBARD AL, Golla H, Lausberg H
    What's in a name? That which we call Multiple Sclerosis Fatigue.
    Mult Scler. 2020 Jul 16:1352458520941481. doi: 10.1177/1352458520941481.
    >> Share

  469. PEETERS LM, Parciak T, Walton C, Geys L, et al
    COVID-19 in people with multiple sclerosis: A global data sharing initiative.
    Mult Scler. 2020 Jul 14:1352458520941485. doi: 10.1177/1352458520941485.
    >> Share

  470. HIDALGO DE LA CRUZ M, Valsasina P, Gobbi C, Gallo A, et al
    Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study.
    Mult Scler. 2020 Jul 14:1352458520940548. doi: 10.1177/1352458520940548.
    >> Share

  471. BARCELLOS LF, Horton M, Shao X, Bellesis KH, et al
    A validation study for remote testing of cognitive function in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520937385. doi: 10.1177/1352458520937385.
    >> Share

  472. LOONSTRA FC, Hoitsma E, van Kempen ZL, Killestein J, et al
    COVID-19 in multiple sclerosis: The Dutch experience.
    Mult Scler. 2020 Jul 14:1352458520942198. doi: 10.1177/1352458520942198.
    >> Share

  473. STORELLI L, Pagani E, Preziosa P, Filippi M, et al
    Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging.
    Mult Scler. 2020 Jul 14:1352458520938999. doi: 10.1177/1352458520938999.
    >> Share

  474. ABBATEMARCO JR, Griffin A, Jones NG, Hartman J, et al
    Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: A single-center experience.
    Mult Scler. 2020 Jul 14:1352458520936912. doi: 10.1177/1352458520936912.
    >> Share

  475. WU P, Li R, Zhang W, Lu H, et al
    Mendelian randomization analysis does not support a role for leptin in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520938990. doi: 10.1177/1352458520938990.
    >> Share

  476. PINTER D, Khalil M, Pirpamer L, Damulina A, et al
    Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520941474. doi: 10.1177/1352458520941474.
    >> Share

  477. CROTEAU D, Tobenkin A, Brinker A, Kortepeter CM, et al
    Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
    Mult Scler. 2020 Jul 14:1352458520938354. doi: 10.1177/1352458520938354.
    >> Share

  478. GERALDES R
    Two-armed active comparator trials are unethical in pediatric multiple sclerosis - No.
    Mult Scler. 2020 Jul 10:1352458520931784. doi: 10.1177/1352458520931784.
    >> Share

  479. WAUBANT E
    Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary.
    Mult Scler. 2020 Jul 10:1352458520936243. doi: 10.1177/1352458520936243.
    >> Share

  480. KRUPP LB, Charvet LE
    Two-armed active comparator trials are unethical in pediatric multiple sclerosis - Yes.
    Mult Scler. 2020 Jul 10:1352458520931796. doi: 10.1177/1352458520931796.
    >> Share

  481. CHITNIS T, Banwell B, Krupp L, Arnold DL, et al
    Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study.
    Mult Scler. 2020 Jul 7:1352458520936934. doi: 10.1177/1352458520936934.
    >> Share

  482. FITZGERALD KC, Morris B, Soroosh A, Balshi A, et al
    Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.
    Mult Scler. 2020 Jul 7:1352458520936226. doi: 10.1177/1352458520936226.
    >> Share

  483. HACOHEN Y, Banwell B, Ciccarelli O
    What does first-line therapy mean for paediatric multiple sclerosis in the current era?
    Mult Scler. 2020 Jul 7:1352458520937644. doi: 10.1177/1352458520937644.
    >> Share

  484. KUNCHOK A, Flanagan EP, Snyder M, Saadeh R, et al
    Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD.
    Mult Scler. 2020 Jul 7:1352458520933884. doi: 10.1177/1352458520933884.
    >> Share

  485. BSTEH G, Berek K, Hegen H, Altmann P, et al
    Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis.
    Mult Scler. 2020 Jul 2:1352458520935724. doi: 10.1177/1352458520935724.
    >> Share

  486. THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
    Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
    Mult Scler. 2020 Jul 2:1352458520936231. doi: 10.1177/1352458520936231.
    >> Share

  487. ARRAMBIDE G
    MOG-antibody-associated disease-getting the whole picture.
    Mult Scler. 2020;26:1000-1001.
    >> Share

    June 2020
  488. FEINSTEIN A, Meza C, Stefan C, Staines WR, et al
    Discontinuing cannabis improves depression in people with multiple sclerosis: A short report.
    Mult Scler. 2020 Jun 26:1352458520934070. doi: 10.1177/1352458520934070.
    >> Share

  489. SIGNORI A, Boffa G, Bovis F, Mariottini A, et al
    Prevalence of disability improvement as a potential outcome for multiple sclerosis trials.
    Mult Scler. 2020 Jun 26:1352458520936236. doi: 10.1177/1352458520936236.
    >> Share


  490. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
    Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
    >> Share

  491. MEHNDIRATTA A, Treaba CA, Barletta V, Herranz E, et al
    Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI.
    Mult Scler. 2020 Jun 25:1352458520932804. doi: 10.1177/1352458520932804.
    >> Share

  492. BOVE R, Rowles W, Zhao C, Anderson A, et al
    A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study.
    Mult Scler. 2020 Jun 25:1352458520930371. doi: 10.1177/1352458520930371.
    >> Share

  493. WIENDL H, Spelman T, Butzkueven H, Kappos L, et al
    Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
    Mult Scler. 2020 Jun 24:1352458520926869. doi: 10.1177/1352458520926869.
    >> Share

  494. GLUKHOVSKY L, Brandstadter R, Leavitt VM, Krieger S, et al
    Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis.
    Mult Scler. 2020 Jun 22:1352458520922830. doi: 10.1177/1352458520922830.
    >> Share

  495. SASTRE-GARRIGA J, Tintore M, Montalban X
    Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
    Mult Scler. 2020 Jun 19:1352458520931785. doi: 10.1177/1352458520931785.
    >> Share

  496. LEVIN SN, Ezuma C, Levine L, Vargas WS, et al
    Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
    Mult Scler. 2020 Jun 19:1352458520927631. doi: 10.1177/1352458520927631.
    >> Share

  497. GHEZZI A, Banwell B, Bar-Or A, Chitnis T, et al
    Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
    Mult Scler. 2020 Jun 19:1352458520932798. doi: 10.1177/1352458520932798.
    >> Share

  498. BHARGAVA P, Nogueras-Ortiz C, Kim S, Delgado-Peraza F, et al
    Synaptic and complement markers in extracellular vesicles in multiple sclerosis.
    Mult Scler. 2020 Jun 17:1352458520924590. doi: 10.1177/1352458520924590.
    >> Share

  499. RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
    Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
    Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
    >> Share

  500. YAVARPOUR-BALI H, Ghasemi-Kasman M
    The role of inflammasomes in multiple sclerosis.
    Mult Scler. 2020 Jun 16:1352458520932776. doi: 10.1177/1352458520932776.
    >> Share

  501. GHEZZI A, Amato MP, Edan G, Hartung HP, et al
    The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
    Mult Scler. 2020 Jun 16:1352458520930620. doi: 10.1177/1352458520930620.
    >> Share

  502. LE M, Malpas C, Sharmin S, Horakova D, et al
    Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
    Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955.
    >> Share

  503. IACOBAEUS E, Arrambide G, Pia Amato M, Derfuss T, et al
    Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
    Mult Scler. 2020 Jun 12:1352458520925369. doi: 10.1177/1352458520925369.
    >> Share

  504. ARRAMBIDE G, Iacobaeus E, Amato MP, Derfuss T, et al
    Aggressive multiple sclerosis (2): Treatment.
    Mult Scler. 2020 Jun 12:1352458520924595. doi: 10.1177/1352458520924595.
    >> Share

  505. LIZAK N, Hodgkinson S, Butler E, Lechner-Scott J, et al
    Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Mult Scler. 2020 Jun 12:1352458520921087. doi: 10.1177/1352458520921087.
    >> Share

  506. POLAT DUNYA C, Tulek Z, Kurtuncu M, Panicker JN, et al
    Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder.
    Mult Scler. 2020 Jun 9:1352458520926666. doi: 10.1177/1352458520926666.
    >> Share

  507. SOLARI A, Oliver D
    Palliative care in multiple sclerosis: European guideline.
    Mult Scler. 2020 Jun 9:1352458520926467. doi: 10.1177/1352458520926467.
    >> Share

  508. XU Y, Hiyoshi A, Brand JS, Smith KA, et al
    Higher body mass index at ages 16 to 20 years is associated with increased risk of a multiple sclerosis diagnosis in subsequent adulthood among men.
    Mult Scler. 2020 Jun 8:1352458520928061. doi: 10.1177/1352458520928061.
    >> Share

  509. BROWN J, Quattrochi B, Everett C, Hong BY, et al
    Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis.
    Mult Scler. 2020 Jun 8:1352458520928301. doi: 10.1177/1352458520928301.
    >> Share

  510. CELIUS EG
    Breastfeeding and treatment of multiple sclerosis.
    Mult Scler. 2020 Jun 8:1352458520931786. doi: 10.1177/1352458520931786.
    >> Share

  511. PIHL-JENSEN G, Wanscher B, Frederiksen JL
    Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis.
    Mult Scler. 2020 Jun 8:1352458520917924. doi: 10.1177/1352458520917924.
    >> Share

  512. ROJAS JI, Patrucco L, Alonso R, Garcea O, et al
    Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
    Mult Scler. 2020 Jun 2:1352458520924586. doi: 10.1177/1352458520924586.
    >> Share

  513. OH J, Chen M, Cybulsky K, Suthiphosuwan S, et al
    Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.
    Mult Scler. 2020 Jun 1:1352458520923970. doi: 10.1177/1352458520923970.
    >> Share

  514. COSTELLO F, Petzold A
    Weighting evidence in MS: Obesity and neurodegeneration.
    Mult Scler. 2020;26:748-750.
    >> Share

  515. BOYKO A
    Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group.
    Mult Scler. 2020;26:869-870.
    >> Share

  516. DE STEFANO N
    Response to Dr Boyko's letter: 'Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as highly MS-risk group'.
    Mult Scler. 2020;26:871.
    >> Share

  517. VAN DER WALT A
    Addressing the treatment gap in MS-associated tremor: A new door opens.
    Mult Scler. 2020;26:858.
    >> Share

    May 2020
  518. VARGAS WS, Noble KG, Banwell B, De Jager P, et al
    The educational impact of childhood-onset multiple sclerosis: Why assessing academic achievement is imperative.
    Mult Scler. 2020 May 28:1352458520923946. doi: 10.1177/1352458520923946.
    >> Share

  519. VON WYL V, Benkert P, Moser A, Lorscheider J, et al
    Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
    Mult Scler. 2020 May 28:1352458520918489. doi: 10.1177/1352458520918489.
    >> Share

  520. CARANDINI T, Pietroboni AM, Sacchi L, De Riz MA, et al
    Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
    Mult Scler. 2020 May 28:1352458520926459. doi: 10.1177/1352458520926459.
    >> Share

  521. PASQUA G, Tommasin S, Bharti K, Ruggieri S, et al
    Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis.
    Mult Scler. 2020 May 28:1352458520922770. doi: 10.1177/1352458520922770.
    >> Share

  522. AYRIGNAC X, Larochelle C, Keezer M, Roger E, et al
    Frailty in ageing persons with multiple sclerosis.
    Mult Scler. 2020 May 27:1352458520923945. doi: 10.1177/1352458520923945.
    >> Share

  523. CORONADO I, Gabr RE, Narayana PA
    Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis.
    Mult Scler. 2020 May 22:1352458520921364. doi: 10.1177/1352458520921364.
    >> Share

  524. WANG FM, Davis MF, Briggs FB
    Predicting self-reported depression after the onset of multiple sclerosis using genetic and non-genetic factors.
    Mult Scler. 2020 May 18:1352458520921073. doi: 10.1177/1352458520921073.
    >> Share

  525. BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
    Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
    Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
    >> Share

  526. VALBURG C, Sonti A, Stern JN, Najjar S, et al
    Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review.
    Mult Scler. 2020 May 14:1352458520923955. doi: 10.1177/1352458520923955.
    >> Share

  527. KILJAN S, Preziosa P, Jonkman LE, van de Berg WD, et al
    Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
    Mult Scler. 2020 May 11:1352458520918978. doi: 10.1177/1352458520918978.
    >> Share

  528. GHARAKHANLOU R, Wesselmann L, Rademacher A, Lampit A, et al
    Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials.
    Mult Scler. 2020 May 11:1352458520917935. doi: 10.1177/1352458520917935.
    >> Share

  529. LUNEMANN JD, Diaz-Diaz J, Stankoff B, Young C, et al
    Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
    Mult Scler. 2020 May 4:1352458520918377. doi: 10.1177/1352458520918377.
    >> Share

  530. BOSE G, Thebault S, Rush CA, Atkins HL, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Mult Scler. 2020 May 4:1352458520917936. doi: 10.1177/1352458520917936.
    >> Share

  531. LAMBE J, Saidha S, Bermel RA
    Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials.
    Mult Scler. 2020;26:624-639.
    >> Share

  532. HARTUNG HP, Mares J, Barnett MH
    Alemtuzumab: Rare serious adverse events of a high-efficacy drug.
    Mult Scler. 2020;26:737-740.
    >> Share

  533. KRIEGER SC, Sumowski JF
    Toward biologically meaningful categories of MS-related fatigue.
    Mult Scler. 2020;26:620-621.
    >> Share

  534. PROSCHMANN U, Sehr T, Akgun K, Ziemssen T, et al
    Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".
    Mult Scler. 2020;26:741-742.
    >> Share

    April 2020
  535. FOX E, Lovett-Racke AE, Gormley M, Liu Y, et al
    A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Mult Scler. 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
    >> Share

  536. KALB R, Brown TR, Coote S, Costello K, et al
    Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
    Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
    >> Share

  537. AHRABIAN D, Neill L, Bell R, Leary SM, et al
    Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519855725. doi: 10.1177/1352458519855725.
    >> Share

  538. FILIPPATOU AG, Lambe J, Sotirchos ES, Fitzgerald KC, et al
    Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519900942. doi: 10.1177/1352458519900942.
    >> Share

  539. UHER T, McComb M, Galkin S, Srpova B, et al
    Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
    Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
    >> Share

  540. YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
    Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
    Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
    >> Share

  541. BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
    Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
    Mult Scler. 2020;26:397-404.
    >> Share

  542. SOLOMON AJ
    Progress towards a diagnostic biomarker for MS: Central vein sign.
    Mult Scler. 2020;26:394-396.
    >> Share

  543. LEVY M
    Expanding the spectrum of MOG antibody disease.
    Mult Scler. 2020;26:515-516.
    >> Share

    March 2020
  544. HEALY BC, Barker L, Bakshi R, Benedict RHB, et al
    Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
    Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439.
    >> Share

  545. TREMLETT H, Marrie RA
    The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities.
    Mult Scler. 2020 Mar 31:1352458520914844. doi: 10.1177/1352458520914844.
    >> Share

  546. MOTL RW, Sandroff BM, Benedict RH, Hubbard EM, et al
    Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
    Mult Scler. 2020 Mar 31:1352458520914822. doi: 10.1177/1352458520914822.
    >> Share

  547. DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
    Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
    >> Share

  548. JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
    Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
    Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
    >> Share

  549. DADAR M, Narayanan S, Arnold DL, Collins DL, et al
    Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
    >> Share

  550. OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
    Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
    >> Share

  551. PEREZ T, Rico A, Boutiere C, Maarouf A, et al
    Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
    Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
    >> Share

  552. SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
    Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
    Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
    >> Share

  553. SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
    Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
    Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
    >> Share

  554. BERTOLI M, Tecchio F
    Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
    Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
    >> Share

  555. DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
    Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
    Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
    >> Share

  556. NG HS, Kingwell E, Zhu F, Zhang T, et al
    Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
    Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
    >> Share

  557. ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
    Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
    Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
    >> Share

  558. FUJIHARA K
    MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary.
    Mult Scler. 2020;26:276-278.
    >> Share

  559. LEITE MI, Sato DK
    MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
    Mult Scler. 2020;26:272-274.
    >> Share

  560. COBO-CALVO A, Marignier R
    MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
    Mult Scler. 2020;26:274-276.
    >> Share

  561. DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
    Spontaneous multiple cervical artery dissections after alemtuzumab.
    Mult Scler. 2020;26:381-383.
    >> Share

  562. CHIARAVALLOTI ND, Moore NB, DeLuca J
    The efficacy of the modified Story Memory Technique in progressive MS.
    Mult Scler. 2020;26:354-362.
    >> Share

  563. ROSSOR T, Benetou C, Wright S, Duignan S, et al
    Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis.
    Mult Scler. 2020;26:333-342.
    >> Share

    February 2020
  564. POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
    Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
    Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
    >> Share

  565. FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
    Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
    Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
    >> Share

  566. HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
    ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
    >> Share

  567. BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
    Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
    >> Share

  568. MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
    Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
    Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
    >> Share

  569. MCKEON A, Zekeridou A
    Autoimmune encephalitis management: MS centers and beyond.
    Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
    >> Share

  570. SON M, McEwan L, Ubaidat M, Bovell K, et al
    Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
    >> Share

  571. BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
    Leptin levels are associated with multiple sclerosis risk.
    Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
    >> Share

  572. MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
    Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
    >> Share

  573. THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
    MSJ 2020 - Editorial comment.
    Mult Scler. 2020;26:134.
    >> Share

  574. LUBLIN F
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
    Mult Scler. 2020;26:163-164.
    >> Share

  575. SORMANI MP
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
    Mult Scler. 2020;26:161-162.
    >> Share

  576. KALINCIK T
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
    Mult Scler. 2020;26:159-161.
    >> Share

    January 2020
  577. CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
    A critical analysis of helminth immunotherapy in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
    >> Share

  578. BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
    Recovery of cognitive function after relapse in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
    >> Share

  579. CARNERO CONTENTTI E, Giachello S, Correale J
    Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
    Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
    >> Share

  580. SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
    Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
    >> Share

  581. CORTESE R, Tur C, Prados F, Schneider T, et al
    Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
    >> Share

  582. SALTER A, Fox RJ, Tyry T, Cutter G, et al
    New applications for independent activities of daily living in measuring disability in multiple sclerosis.
    Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
    >> Share

  583. WARNKE C, Hartung HP
    Big data in MS-What can we learn from large international observational studies such as MSBase?
    Mult Scler. 2020;26:4-5.
    >> Share

  584. REDDEL SW
    Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
    Mult Scler. 2020;26:126-127.
    >> Share

  585. VUKUSIC S, Casey R, Rollot F, Brochet B, et al
    Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
    Mult Scler. 2020;26:118-122.
    >> Share

  586. MELI R, Roccatagliata L, Capello E, Bruschi N, et al
    Ecological impact of isolated cognitive relapses in MS.
    Mult Scler. 2020;26:114-117.
    >> Share

  587. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders.
    Mult Scler. 2020;26:128-129.
    >> Share

    December 2019
  588. CROUSE DL, Foroughi I, Gupta N
    Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
    Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
    >> Share

  589. COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
    High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
    Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
    >> Share

  590. KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
    Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
    Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
    >> Share

  591. KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
    Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
    Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
    >> Share

  592. HOLTON KF, Kirkland AE
    Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
    Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
    >> Share

  593. RAHNAMA'I MS
    Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
    Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
    >> Share

  594. BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
    Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
    Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
    >> Share

    November 2019
  595. GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
    Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
    Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
    >> Share

  596. WALLACH AI, Waltz M, Casper TC, Aaen G, et al
    Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
    Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
    >> Share

  597. LI CMF, Hung PS, Chu PP, Tohyama S, et al
    Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
    Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
    >> Share

  598. COMI G, Alroughani R, Boster AL, Bass AD, et al
    Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
    Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
    >> Share

  599. KIM JE, Park SH, Han K, Kim HJ, et al
    Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
    Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
    >> Share

  600. BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
    Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
    Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
    >> Share

  601. BAETGE SJ, Filser M, Renner A, Ullrich S, et al
    On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
    Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
    >> Share

  602. BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
    Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
    >> Share

  603. PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
    Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
    Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
    >> Share

  604. CORDANI C, Valsasina P, Preziosa P, Meani A, et al
    Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
    Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
    >> Share

  605. COLLORONE S, Cawley N, Grussu F, Prados F, et al
    Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
    Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
    >> Share

  606. NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
    Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
    >> Share

  607. KUHLE J, Plavina T, Barro C, Disanto G, et al
    Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
    >> Share

  608. VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
    Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
    >> Share

    October 2019
  609. RYAN JM, Fortune J, Stennett A, Kilbride C, et al
    Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
    Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
    >> Share

  610. LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
    eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
    >> Share

  611. ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
    Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
    >> Share

  612. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
    >> Share

  613. JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
    Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
    Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
    >> Share

  614. JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
    Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
    >> Share

  615. DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
    Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
    >> Share

  616. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
    Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
    Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
    >> Share

  617. ZECCA C, Bovis F, Novi G, Capobianco M, et al
    Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
    >> Share

    July 2019
  618. KANG Y, Gauthier SA
    PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
    Mult Scler. 2019;25:1090-1091.
    >> Share

    June 2019
  619. GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
    T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
    Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
    >> Share

  620. ZEYDAN B, Kantarci OH
    MS progression is predominantly driven by age-related mechanisms - Commentary.
    Mult Scler. 2019;25:906-908.
    >> Share

    April 2019
  621. MANOUSAKI D, Richards JB
    Vitamin D deficiency is an etiological factor for MS - Yes.
    Mult Scler. 2019;25:637-639.
    >> Share

  622. LANGER-GOULD A, Lucas RM
    Vitamin D deficiency is an etiological factor for MS - No.
    Mult Scler. 2019;25:639-641.
    >> Share

  623. WILLIAMS T, Chataway J
    Immune-mediated encephalitis with daclizumab: The final nail.
    Mult Scler. 2019;25:753-754.
    >> Share

  624. THOUVENOT E, Hinsinger G, Demattei C, Uygunoglu U, et al
    Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
    Mult Scler. 2019;25:669-677.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016